• Editas Medicine Inc EDIT.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -23 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -87 cents to 10 cents per share.

• Revenue fell 49% to $30.60 million from a year ago; analysts expected $32.23 million.

• Editas Medicine Inc's reported EPS for the quarter was a loss of 55 cents​.

• The company reported a quarterly loss of $45.4 million.

• Editas Medicine Inc shares had risen by 38.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 14.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 9 "hold" and 2 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Editas Medicine Inc is $3.50

This summary was machine generated from LSEG data March 5 at 11:25 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)